Our Editorial Board member, Raffaele Califano (The Christie NHS Foundation Trust) joined us at ESMO 2019 to highlight results from the FLAURA study in NSCLC (NCT02296125).
Questions
1. Please describe the FLAURA trail and its reported results? (0:04)
2. Clinically, what impact do you think osimertinib will have over existing standard of care for patients with NSCLC? (3:00)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Raffaele Califano has acted as a consultant and advisor for AstraZeneca and BMS.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
